


#17 B/Per

Attorney's Docket No. 5800-79 (35800/191890)

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Glucksmann *et al.*

Confirmation No.: 5331

Appl. No.: 09/495,823

Group Art Unit: 1652

Filed: January 31, 2000

Examiner: Yong D. Pak

For: 22438, 23553, 25278 AND 26212 NOVEL HUMAN SULFATASES

January 23, 2003

RECEIVED

FEB 03 2003

Commissioner for Patents
Washington, DC 20231

TECH CENTER 1600/2900

AMENDMENT

Sir:

In response to the Office Action mailed July 26, 2002, reexamination and reconsideration of the above-identified application are requested in view of the following amendments and remarks. The Examiner is respectfully requested to enter the following amendments.

In The Specification:

Please amend the paragraph beginning on page 6, line 4, to read as follows:

Novel sulfatase nucleotide sequences, and the deduced sulfatase polypeptides are described herein. Accordingly, the invention provides isolated sulfatase nucleic acid molecules having the sequences shown in SEQ ID NOS:2, 4, 6, and 8 or in the cDNA deposited with ATCC as Patent Deposit Number PTA-1639 (which corresponds with SEQ ID NO:4), or PTA-1846 (which corresponds with SEQ ID NO:6) ("the deposited cDNA"), and variants and fragments thereof.

Please amend the paragraph beginning on page 11, line 13, to read as follows:

Plasmids containing the sulfatase cDNA inserts were deposited with the Patent Depository of the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, Virginia, on April 5, 2000 or May 9, 2000 and assigned Patent Deposit Numbers PTA-1639 or PTA-1846, respectively. The deposits will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the